Market Dynamics

Gradual increase in  number of patients suffering from chronic Alzheimer and demand for advanced treatment are major factors expected to drive the growth of global muscarinic acetylcholine receptor market. More than 6 million Americans of all ages have Alzheimer's. An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia in 2021. Seventy-two percent are age 75 or older. Government is investing high for R&D activities and development of advanced treatment in order to treat chronic disorder. Rapid advancements in the field of muscarinic acetylcholine receptors that regulate many fundamental central and peripheral functions for treatment of Alzheimer are gaining importance. Loss of forebrain acetylcholine (ACh) is common symptom in Alzheimer. Use of specific agonists and antagonists of muscarinic receptors are discussed as possible treatment options in DAT. Players are investing high for development of novel therapies, their approach towards collaborative work with healthcare organization in order to treat patients is expected to impact the growth of muscarinic acetylcholine receptor market. High ratio of successful clinical trials form the players is expected to boost the growth of target market. In 2019, Karuna Therapeutics, Inc. completed a Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia, EMERGENT-1. In 2020, the company has initiated the first Phase 3 trial in the EMERGENT program.

Rapid innovation in healthcare sector, increase in number of patients suffering from chronic obstructive pulmonary disease and attention deficit hyperactivity disorder are introduction of new therapeutic solutions are factors expected to augment the muscarinic acetylcholine receptor market growth. Factors such as high cost of R&D and stringent government regulations related to product approval are expected to hamper the growth of global muscarinic acetylcholine receptor market. In addition, lack of advanced infrastructure for R&D activities in developing countries is expected to challenge the growth of target market. However, high investment by major players for R&D activities and rise in clinical trials related to successful medications are factors expected to create new opportunities for players operating in muscarinic acetylcholine receptor market over the forecast period. In addition, increasing partnership and agreements between regional and international players is expected to support the revenue transaction of target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global muscarinic acetylcholine receptor market due to high patient pool suffering from COPD and other disorders. In the United States, an estimated 16 million adults have COPD. However, that may be an underestimate. The American Lung Association (ALA) thinks there may be as many as 24 million American adults living with COPD. In addition, More than 7 million U.S. women have COPD, and millions more are believed to have symptoms, yet haven’t been diagnosed. According to Alzheimer's Association, by 2050, the number of people age 65 and older with Alzheimer’s dementia may grow to a projected 12.7 million. Increasing consumer spending on healthcare and availability of favorable reimbursement policies are factors expected to impact the growth of target market. In addition, availability of advanced infrastructure for R&D activities and introduction of innovative solutions is expected to boost the muscarinic acetylcholine receptor market growth.

The market in Asia Pacific is expected to witness faster growth in the muscarinic acetylcholine receptor market due to high government spending on development of healthcare sector. Increasing awareness among consumers related to advanced treatment and high spending on healthcare are factors expected to impact the regional market growth. In addition, increase in geriatric population and demand for advanced treatment is expected to impact the growth of muscarinic acetylcholine receptor market. Increasing merger & acquisition activities by players and focus on increasing the customer base is expected to support the market growth.

Competitive Landscape      

The global muscarinic acetylcholine receptor market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Muscarinic Acetylcholine Receptor Market Segment Analysis, 2019

The global muscarinic acetylcholine receptor market is segmented into type and application. The type segment is bifurcated into M1, M4, M5, and others. Among type the M5 segment is expected to account for noticeable revenue share in the global muscarinic acetylcholine receptor market. The application segment is divided into Chronic Obstructive Pulmonary Disease (COPD), Attention Deficit Hyperactivity Disorder, Alzheimer’s disease, Memory Impairment, Psychiatric Disorders, and others. Among application the Alzheimer’s disease segment is expected to account for significant revenue share in the target market. The players profiled in the report are Heptares Therapeutics Ltd., Sumitomo Dainippon Pharma Co. Ltd., Anavex Life Sciences Corp., NeuroHealing Pharmaceuticals Inc., AstraZeneca Plc., and Karuna Pharmaceuticals Inc.

Market Segmentation

Market By Type

M1
M4
M5
Others

Market By Application

Chronic Obstructive Pulmonary Disease (COPD)
Attention Deficit Hyperactivity Disorder
Alzheimer’s Disease
Memory Impairment
Psychiatric Disorders
Others

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa